Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taro earnings

This article was originally published in The Tan Sheet

Executive Summary

Hawthorne, N.Y.-based firm cites advertising expenses in support of ElixSure cough/cold and Kerasal moisturizer lines as a reason for an approximate 55% reduction in first-quarter net earnings to $5 mil. Overall sales declined approximately 7% to $84.1 mil., Taro reported April 26. The costs were incurred prior to the product lines' March divestment, the company maintains. Taro turned over North American marketing and distribution rights for the lines to Alterna in March (1"The Tan Sheet" March 7, 2005, p. 11)...

You may also be interested in...

Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture

Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market

Facing Shortage, FDA Further Relaxes Face Mask, Face Shield And Respirator Guidance

As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers

Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow

FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts